Chronic traumatic encephalopathy research has been constrained by a problem that is both scientific and practical: the disease can only be confirmed after death. That has limited efforts to develop treatments or prevention strategies, because researchers have lacked a way to identify living patients with certainty.
New data published Thursday offer an early route around that barrier. In a study built around 21 football players who donated blood while alive and later donated their brains to the Boston University CTE Center Brain Bank, researchers found that a specific tau species in blood was elevated in people who were later confirmed by autopsy to have CTE.
Of the 21 participants, 18 had confirmed CTE at autopsy, and 16 of those had advanced disease. Researchers reported that a form of tau called eMTBR-tau was elevated in the blood of the 18 volunteers with CTE relative to those who did not have the disease. They also found that participants with advanced CTE had higher blood levels of eMTBR-tau than those with mild CTE.
The data
The signal here is not that a clinical blood test is ready. The study is instead an early validation exercise in a field that has lacked any live-diagnosis standard at all. Because every participant ultimately underwent autopsy-based assessment, the work gave researchers a way to compare blood findings against the pathology definition of the disease.
That design matters. CTE has been difficult to study precisely because many biomarker efforts in neurodegeneration rely on comparisons to diagnoses made during life, while this disease still depends on post-mortem confirmation. By linking ante-mortem blood samples to autopsy results, the researchers created a rarer kind of dataset for this indication.
The severity split is also important. The study did not only separate confirmed CTE from no CTE; it also found higher eMTBR-tau levels in advanced disease than in mild disease. If that pattern holds up in larger cohorts, a future assay could be useful not only for detection but also for stratifying patients in research settings.
Why It Matters
For companies and academic groups trying to build therapies, diagnostics often determine whether a field can become commercially and clinically organized. Without a way to identify living patients, trial enrollment, patient selection, and treatment monitoring all become harder. A blood-based marker would not solve every problem, but it could turn CTE from an autopsy-defined condition into one that can be studied prospectively.
The findings remain preliminary, and the source material is explicit on that point. Gil Rabinovici Edward, a co-author at the University of California San Francisco, said in a statement that there is “still much work to do to validate these findings before the test is ready to use in patients.” He added that he is “very hopeful that this study marks a major milestone in our ability to diagnose and ultimately treat this devastating disease.”
That is the right frame for the result. The immediate significance is less about imminent clinical adoption than about whether CTE research can begin to use blood biomarkers the way other neurodegenerative fields already do. If eMTBR-tau continues to perform in larger studies, the biggest impact may be operational: making future interventional research more feasible than it has been when the disease could only be confirmed after death.




